EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Efficacy and Safety of Finerenone Combined with Dapagliflozin in the Treatment of Non-Diabetic Chronic Kidney Disease: A Single-Center Retrospective Study

Jianwei Ma, Qin Su, Hanlu Wang, Jiayan Xu, Chenyi Yuan, Guicai Fan iD, Jiapei Ying, Xueyan Bian

Drug Design, Development and Therapy · 2026

DOI: 10.2147/dddt.s564942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Jianwei Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, People's Republic of China. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Renal Insufficiency, Chronic, Naphthyridines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesRenal Insufficiency, ChronicNaphthyridinesHumansRetrospective StudiesFemaleMaleMiddle AgedDrug Therapy, CombinationAgedGlomerular Filtration RateSodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

albuminuriadapagliflozinestimated glomerular filtration ratefinerenonenon-diabetic chronic kidney disease

Substanzen

dapagliflozinBenzhydryl CompoundsGlucosidesfinerenoneNaphthyridinesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Nephrology, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, People's Republic of China.
  • Department of Clinical Medicine, Tongji University School of Medicine, Shanghai, 200092, People's Republic of China.
  • Health Science Center, Ningbo University, Ningbo, 315211, People's Republic of China.

ORCID-Profile: Guicai Fan

Zitieren

APA

Ma, J., Su, Q., Wang, H., Xu, J., Yuan, C., Fan, G., Ying, J., & Bian, X. (2026). Efficacy and Safety of Finerenone Combined with Dapagliflozin in the Treatment of Non-Diabetic Chronic Kidney Disease: A Single-Center Retrospective Study. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s564942

Vancouver

Ma J, Su Q, Wang H, Xu J, Yuan C, Fan G, et al. Efficacy and Safety of Finerenone Combined with Dapagliflozin in the Treatment of Non-Diabetic Chronic Kidney Disease: A Single-Center Retrospective Study. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s564942

BibTeX
@article{Ma2026,
  author = {Ma, Jianwei and Su, Qin and Wang, Hanlu and Xu, Jiayan and Yuan, Chenyi and Fan, Guicai and Ying, Jiapei and Bian, Xueyan},
  title = {Efficacy and Safety of Finerenone Combined with Dapagliflozin in the Treatment of Non-Diabetic Chronic Kidney Disease: A Single-Center Retrospective Study},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  doi = {10.2147/dddt.s564942}
}
Kostenlos starten →